2020
Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis
Morales DR, Conover MM, You SC, Pratt N, Kostka K, Duarte-Salles T, Fernández-Bertolín S, Aragón M, DuVall SL, Lynch K, Falconer T, van Bochove K, Sung C, Matheny ME, Lambert CG, Nyberg F, Alshammari TM, Williams AE, Park RW, Weaver J, Sena AG, Schuemie MJ, Rijnbeek PR, Williams RD, Lane JCE, Prats-Uribe A, Zhang L, Areia C, Krumholz HM, Prieto-Alhambra D, Ryan PB, Hripcsak G, Suchard MA. Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. The Lancet Digital Health 2020, 3: e98-e114. PMID: 33342753, PMCID: PMC7834915, DOI: 10.1016/s2589-7500(20)30289-2.Peer-Reviewed Original ResearchAngiotensin receptor blockersCalcium channel blockersAcute respiratory distress syndromeAcute kidney injuryHospital admissionRespiratory distress syndromeCOVID-19 diagnosisKidney injuryDistress syndromeDrug classesCohort analysisCOVID-19Renin-angiotensin system blockersThiazide-like diureticsBaseline patient characteristicsUse of ACEIsPost-authorisation studiesUK National InstituteRelative risk differenceNational InstituteCombination useMedical Research CouncilAustralian National HealthElectronic health recordsAntihypertensive users
2019
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis
Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. The Lancet 2019, 394: 1816-1826. PMID: 31668726, PMCID: PMC6924620, DOI: 10.1016/s0140-6736(19)32317-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCalcium Channel BlockersChildCohort StudiesComparative Effectiveness ResearchDatabases, FactualDiureticsEvidence-Based MedicineFemaleHeart FailureHumansHypertensionMaleMiddle AgedMyocardial InfarctionStrokeYoung AdultConceptsNon-dihydropyridine calcium channel blockersCalcium channel blockersThiazide-like diureticsChannel blockersEnzyme inhibitorsDrug classesHazard ratioCurrent guidelinesFirst-line antihypertensive drug classesComparative effectivenessFirst-line drug classesNew-user cohort designDihydropyridine calcium channel blockerElectronic health record databaseFirst-line classesAngiotensin receptor blockersAntihypertensive drug classesAcute myocardial infarctionHealth record databaseReal-world evidenceMedical Research CouncilMillions of patientsAustralian National HealthOptimal monotherapyReceptor blockers